Introduction
============

Lung cancer is a major cause of mortality worldwide, with more than 1.8 million new cases and almost 1.6 million deaths estimated in 2012 ([@b1-etm-0-0-4773]). The age-standardized incidence rate of lung cancer was 64.8/10^5^ for men and 48.6/10^5^ for women in the USA from 2011 to 2014, while the age-standardized mortality rate was 57.8/10^5^ for men and 37/10^5^ for women ([@b1-etm-0-0-4773],[@b2-etm-0-0-4773]). The incidence rate of lung cancer in China was 63.9/10^5^ for men and 31.9/10^5^ for women in 2011, while the mortality rate was 50.9/10^5^ for men and 23.8/10^5^ for women ([@b3-etm-0-0-4773]). Non-small cell lung cancer (NSCLC) accounts for ≥80% of all lung tumors, and \~66% of patients initially present with an inoperable form of the disease ([@b4-etm-0-0-4773]). Treatment with cisplatin (CDDP)-based chemotherapy (CTH) leads to a 10% increase in the 1-year survival rate and increases median survival time by 2 months. It is currently considered the first line treatment for patients with advanced NSCLC who lack a sensitizing mutation of epidermal growth factor receptor (EGFR) ([@b5-etm-0-0-4773]). The addition of a second drug \[either gemcitabine (GEM), vinorelbine, docetaxel or paclitaxel) generates only small improvements in tumor responses and survival rates ([@b6-etm-0-0-4773]). Recently it was determined that the addition of bevacizumab, a monoclonal antibody for vascular endothelial growth factor, increased the survival and response rates in patients with advanced NSCLC receiving CTH ([@b7-etm-0-0-4773]). However, bevacizumab is expensive and thus may not be developed for wider use ([@b7-etm-0-0-4773]). CTH-induced neutropenia is independently associated with increased survival rates of patients with advanced NSCLC, possibly due to a reduction in tumor-related leukocytosis ([@b8-etm-0-0-4773]--[@b11-etm-0-0-4773]). Neutropenia occurring in patients with early stage breast cancer is also an independent predictor of increased survival ([@b12-etm-0-0-4773]). The mechanisms that the body uses to counter CTH-induced neutropenia remain unknown and may be caused by a combination of factors, such as variations in drug metabolism.

Rikkunshito (also known as TJ-43 or Liu-Jun-Zi-Tang) is a common prescription of traditional Chinese and Japanese Kampo medicines consisting of 8 herbs (*Atractylodis lanceae rhizoma*, *Ginseng radix*, *Pinelliae tuber*, *Hoelen*, *Zizyphi fructus*, *Aurantii nobilis pericarpium*, *Glycyrrhizae radix* and *Zingiberis rhizoma*) and is commonly used to treat gastrointestinal diseases ([@b13-etm-0-0-4773]). It has been demonstrated that rikkunshito ameliorates CDDP-induced anorexia, improves patient quality of life ([@b14-etm-0-0-4773]) and relieves functional dyspepsia via antagonistic action of the 5-Hydroxytryptamine (HT) 2B/2C/3 receptor pathway ([@b15-etm-0-0-4773]--[@b17-etm-0-0-4773]). Rikkunshito has been used to ameliorate anorexic symptoms, such as dysmotility-like dyspepsia, postprandial fullness, early satiety and epigastric burning, in cancer cachexia-anorexia syndrome, particularly in patients with colon and breast cancer ([@b18-etm-0-0-4773],[@b19-etm-0-0-4773]). Intervention with herbs used in traditional Chinese medicine herbs may increase efficacy and reduce toxicity when used in combination with EGFR-tyrosine kinase inhibitor to treat advanced NSCLC ([@b20-etm-0-0-4773]). Thus, it was hypothesized that rikkunshito may be effective at increasing patient responses to treatment and decreasing the side effects of combination CTH in patients with advanced stage NSCLC. In the present study, a randomized double blind clinical trial was conducted to determine whether rikkunshito may be appropriate to use as an adjuvant treatment during chemotherapy for patients with NSCLC. Furthermore, a microarray genomic expression method was used to identify the molecular processes involved in CTH and the whether rikkunshito induced any changes in peripheral blood mononuclear cells (PBMC).

Patients and methods
====================

### Patients

The study participants were recruited from the pulmonary clinics of Kaohsiung Chung Gung Memorial Hospital (Kaohsiung, Taiwan) between August 2007 and January 2009. A total of 17 patients were enrolled in the current study. Patients were aged ≥20 years with histologically confirmed, newly diagnosed, untreated stage IIIB or IV NSCLC based on the international staging system for lung cancer ([@b21-etm-0-0-4773]), ≥1 measurable (uni-dimensional) lesion with a diameter ≥10 mm using spiral computerized tomography and an ECOG performance status ([@b22-etm-0-0-4773]) of 0, 1 or 2. Exclusion criteria included hypersensitivity to any herbal drug, receipt of concurrent immunotherapy or radiotherapy, uncontrolled medical illness and history of other malignancies within the last 5 years. The study protocol followed the guidelines of the Declaration of Helsinki and was approved by the institutional review boards of Kaohsiung Chang Gung Memorial Hospital (certificate no. 96-0363B). All patients provided written informed consent for inclusion in the current study.

### Treatment plan

All enrolled patients were randomly assigned into one of two groups: A CTH+R group (n=9) or a CTH group (n=8). All patients received combination CTH with CDDP (Platinex^®^; Dabur India Limited, New Delhi, India; mean dose 60 mg/m^2^) on day 1 plus GEM (GEMZAR^®^; mean dose 1000 mg/m^2^; Lilly, Indianapolis, IN, USA) on day 1, 8 and 15 of a 28-day cycle, as well as dry powder placebo (corn starch; Chuang Song Zong Pharmaceutical Co., Ltd., Kaohsiung, Taiwan) 30 g administered orally daily (CTH group), or combination chemotherapy plus rikkunshito 30 g administered orally daily (CTH+R group). The powder extract of rikkunshito was a mixture of 5.00 g ginseng radix, 5.00 g atractylodis rhizoma, 5.00 g hoelen, 5.00 g pinelliae tuber, 2.50 g glycyrrhizae radix, 2.50 g auranti nobilis pericarpium, 2.50 g gingiberis rhizoma, 2.50 g zizyphi Fructus and 7.80 g starch for each 100.00 g power with a crude drug: extract ratio of 30.00:7.80 (LIOW JIUN TZYY TANG extract powder; no. 2088; Chuang Song Zong pharmaceutical Co., Ltd.). Treatment was planned for a maximum of six cycles unless discontinued due to disease progression, unacceptable toxicity, physician or patient decision, requirement for palliative radiotherapy or patient mortality. All patients received the 5-HT3 receptor antagonist granisetron (Kytril^®^; 2 mg; TTY Biopharm, Taipei, Taiwan), metoclopramide (Promeran^®^; 7.68 mg; Standard Chem. & Pharm. Co., Ltd., Tainan, Taiwan) and dexamethasone (Methasone^®^; 10 mg; Taiwan Veterans Pharm. Co., Ltd., Chung-Li, Taiwan) as anti-emetic agents in each combination CTH regimen. Following baseline evaluation, tumor status was assessed following last course of chemotherapy, according to the Response Evaluation Criteria in Solid Tumors ([@b23-etm-0-0-4773]). Leukocyte, hemoglobin levels and platelet counts as well as events of subjective toxicity were recorded on day 1, 8 and 15 in each treatment course. Maximum changes in the hematological parameters were defined as the value prior to treatment minus the mean lowest value for each treatment course. Toxicity was graded prior to each treatment cycle using the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0 ([@b24-etm-0-0-4773]). Overall survival (OS) was defined as time from enrollment until mortality from any cause within a 1- to 3-year observation period. Progression-free survival (PFS) was defined as the time from date of randomization to the date of first observation of progression \[defined as ≥20% increase in the sum of the largest diameter of target lesions ([@b23-etm-0-0-4773])\] or mortality due to any cause. The primary endpoint was the treatment response and the categories of the scales of anorexia, nausea, and vomiting \[based on evaluation of event frequency and clinical impact ([@b24-etm-0-0-4773])\] during the treatment course (duration, \~4 months); secondary endpoints included hematological effects (hemoglobin level, white cell count, neutrophil count and platelet count) during the treatment course and whole genome gene expression changes at the end of the treatment course ([@b24-etm-0-0-4773]).

### RNA isolation and cRNA synthesis

Approximately 15 ml peripheral whole blood was collected by a phlebotomist using mini-puncture following four courses of chemotherapy treatment with or without concurrent use of rikkunshito. PBMCs were isolated, washed in PBS, transferred and stored in RNAlater^®^ (Ambion; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at −80°C until RNA isolation. A RiboPure-Blood kit (Ambion; Thermo Fisher Scientific, Inc.) was used to isolate high quality total RNA. Samples were run using an RNA 6000 Nano Gel kit on an Agilent 2100 Bioanalyzer (both from Agilent Technologies, Inc., Santa Clara, CA, USA) to determine RNA quality and 2 µl RNA was used to determine RNA concentration using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Inc.). Only samples with A260/A280 ratios of 1.9 to 2.1 were used for further studies. A total of 300 ng RNA was used for *in vitro* transcription of cRNA using the Illumina^®^ Totalprep™ RNA Amplication kit (Ambion; Thermo Fisher Scientific, Inc.).

### Gene expression profiling

The Illumina HumanRef-8V2 BeadChip (Illumina, Inc., San Diego, CA, USA) was used to generate expression profiles of \>22,000 transcripts with 750 ng labeled cRNA. All expression profiles are available at NCBI Gene Expression Ominibus (GEO; <https://www.ncbi.nlm.nih.gov/geo/>) under the series number GSE18309. The probe sets and genes were grouped into functional categories using the Gene Ontology Biological Processes Classification ([@b25-etm-0-0-4773]).

### Microarray data analysis

Statistical analysis of the microarray data was performed using the GeneSpring™ software version 11 (Sigenics Inc., Chicago, IL, USA). A total of 8,186 probe sets passed the signal filter (which filtered out genes that had low signal close to background level), and were used for further statistical analysis. A non-parametric Wilcoxon signed-rank test for paired comparison of the data prior to and following treatment in the two groups was applied. A change in expression of \>1.5-fold and P\<0.05 was used to define the optimal subsets of significantly up- and down-regulated genes.

### Statistical analysis

Continuous values are presented as mean ± standard deviation. Mann-whitney, Wilcoxon ranked sum, Kruskal-Wallis H and χ^2^ tests were used to assess the differences between different groups, where appropriate. Survival curves were constructed using the Kaplan-Meier method. Cox regression was used to identify independent survival factors. Stepwise multiple linear regression analysis was used to adjust for age, tumor stage, and other confounding factors and obtain adjusted P-values comparing continual variables between the two study groups. All tests were two tailed and P\<0.05 was considered to indicate a significant difference. The SPSS statistical software package version 15.0 (SPSS Inc; Chicago, IL, USA) was used for data analysis.

Results
=======

### Clinical effects of combination chemotherapy with or without rikkunshito in patients with advanced stage NSCLC

Between August 2007 and January 2009, 26 patients with newly diagnosed stage IIIb or IV NSCLC were screened. A total of 9 patients were excluded; 6 refused to participate in the study, 2 had other concomitant malignancies and one was receiving concurrent radiotherapy. A total of 17 patients were thus enrolled in the current study. Patients were randomized to the CTH arm (n=8) or CTH+R arm (n=9) and all patients completed follow-up. One-year survival follow-up was completed in January 2010. Patients in the CTH arm received a median of 4 (range 3--5) cycles of combination chemotherapy and patients in the CTH+R arm received a median of 4 (range 2--6) cycles of combination chemotherapy as well as a daily dose of rikkunshito (cycle numbers of combination chemotherapy, CTH vs. CTH+R arm, P=0.705). The demographic and clinicopathological characteristics of the 17 patients are presented in [Table I](#tI-etm-0-0-4773){ref-type="table"}. Both groups were matched in age, sex, smoking history, tumor stage, ECOG performance status, histopathology subtype, tumor size, co-morbidity and doses of chemotherapy agents administered. Blood cell counts at baseline were similar, apart from significantly lower hemoglobin levels (P=0.014) observed in the CTH+R group compared with the CTH group. Following a median of four courses of chemotherapy, the patients in the CTH+R group experienced greater maximum changes in white cell count (P=0.034) and absolute neutrophil count (P=0.030), compared with patients in the CTH alone group, following adjustment for age, tumor stage and other confounding factors by stepwise multiple linear regression analysis ([Table II](#tII-etm-0-0-4773){ref-type="table"}). This means that patients with NSCLC in the CTH+R group exhibited more severe CTH-induced neutropenia compared with patients in the CTH group. There were no significant differences in other outcomes between the two groups in terms of PFS, OS, treatment response, change in tumor size, subjective adverse reactions and maximum changes in hemoglobin level or platelet count from baseline ([Table II](#tII-etm-0-0-4773){ref-type="table"}). Based on Kaplan-Meier estimates ([Fig. 1A](#f1-etm-0-0-4773){ref-type="fig"}), median PFS was 6 months in both the CTH and CTH+R groups (P=0.390, log-rank test). There was 1 case of patient mortality in the CTH group and 5 cases in the CTH+R group. Median one-year OS was 12 months in the CTH group and 11 months in the CTH+R group (P=0.058, log-rank test; [Fig. 1B](#f1-etm-0-0-4773){ref-type="fig"}). The one-year survival rate was 87.5% for the CTH arm and 44.4% for the CTH+R arm. Multivariate Cox regression analysis determined that old age \[aged \>60 years; hazard ratio 1.095, 95% confidence interval (CI) 1.09--1.189; P=0.030\] was the only independent factor associated with one-year mortality when adjusting for blood laboratory data, tumor stage, ECOG performance status, histology subtype and treatment group. Kaplan-Meier estimates determined that patients aged ≤60 years had a better one-year survival rate than those aged \>60 years (P=0.015, log-rank test; [Fig. 1C](#f1-etm-0-0-4773){ref-type="fig"}). The three-year PFS (median 6 vs. 7 months, P=0.591; [Fig. 2A](#f2-etm-0-0-4773){ref-type="fig"}) and OS (median 27 vs. 15 months, P=0.261; [Fig. 2B](#f2-etm-0-0-4773){ref-type="fig"}) were similar in both groups. Clinical benefit, defined as a complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), as well as the frequency of subjective toxicity events, was similar between all patients in the two arms ([Table II](#tII-etm-0-0-4773){ref-type="table"}). There were 2 (25%) PR cases, 3 (37.5%) SD cases and 3 (37.5%) PD cases in the CTH arm, compared with 4 (44.4%) PR cases, 4 (44.4%) SD cases and 1 (11.1%) PD case in the CTH+R arm (P=0.415).

### Distinct gene expression signature changes associated with Rikkunshito and chemotherapy relative to chemotherapy alone

Gene expression data prior to and following treatment was compared between the CTH+R and CTH groups, respectively and fold change was obtained by dividing the log ratios of gene expression intensity following treatment by the data collected prior to treatment. A total of 159 differentially expressed genes (DEG) were identified to be significantly up or down regulated in the CTH+R group following treatment, which were regulated in the opposite direction or remained unchanged in the CTH group. Among these, 111 genes were up-regulated and 48 genes were down-regulated following rikkunshito treatment. Gene ontology analysis demonstrated that gene sets mapping to defensive responses to other organisms, immune cell killing and serine-type endopeptidase activity pathways were up-regulated following rikkunshito treatment, whereas gene sets mapping to blood coagulation, thrombosis, leukocyte migration and integral component of plasma membrane pathways were down-regulated ([Table III](#tIII-etm-0-0-4773){ref-type="table"}). Genes up-regulated following with rikkunshito treatment ([Table IV](#tIV-etm-0-0-4773){ref-type="table"}) were associated with neutrophil apoptosis \[elastase (*ELANE*), proteinase 3 (*PRTN3*), cathepsin G (*CTSG*), cluster of differentiation (*CD*)24\], cell-killing or bactericidal ability of neutrophil \[defensin α 1--3 (*DEF A1, A2, A3*), bactericidal/permeability-increasing protein (*BPI*)\], natural killer (NK) cell activation \[killer cell immunoglobulin-like receptor (*KIR2DL1*-3), killer cell lectin-like receptor (*KLR*), *KIR2DS5*, *NK group 7* (*NKG7*)\] and B cell proliferation \[*CD19*, membrane-spanning 4-domains (*MS4A3*), *CD79A*, *CD79B* and tumor necrosis factor receptor superfamily (*TNFRSF13B/17*). Genes that were down-regulated following rikkunshito treatment ([Table IV](#tIV-etm-0-0-4773){ref-type="table"}) were associated with neutrophil migration \[prostaglandin endoperoxide synthase 1 (*PTGS1*; cyclooxygenase 1, *COX1*), monophosphoryl lipid A (*MPL*), junctional adhesion molecule 3 (*JAM3*), adhesion molecule interacts with *CXADR* antigen 1 (*AMICA1*; *JAML*)\], coagulation \[coagulation factor XIII (*F13A1*)\], thrombosis \[glycoprotein IX (*GPIX*), platelet factor 4 variant 1 (*PF4V1*), pro-platelet basic protein (*PPBP*), integrin α 2b (*ITGA2B*; *GP IIb* of *IIb/IIIa* complex), glycoprotein Ib (*GP1BB*), *MPL*)\] and type I interferon (*IFN*) signaling \[interferon-induced protein with tetratricopeptide repeats 1 (*IFIT1*), *IFIT2*)\]. Gene interaction analysis demonstrated a consistent result ([Fig. 3](#f3-etm-0-0-4773){ref-type="fig"}), indicating that rikkunshito may inhibit neutrophil migration by down-regulating *MPL*, *PTGS1*, *AMICA1*, *JAM3* and *IFIT*, while enhancing the cell-killing ability of neutrophils by up-regulating *ELANE*, *PREN3*, *BPI* and *DEF*.

Discussion
==========

Rikkunshito is a Chinese and Japanese herbal medicine that is widely used to treat upper gastrointestinal symptoms, including functional dyspepsia, gastroesophageal reflux disease, dyspeptic symptoms in patients following post gastrointestinal surgery, and chemotherapy-induced dyspepsia in patients with cancer ([@b18-etm-0-0-4773],[@b19-etm-0-0-4773]). The anti-emetic effect of rikkunshito occurs via the stimulation of endogenous ghrelin secretion by blocking the serotonin (5-HT) 2b/2c/3 receptor pathway and inhibiting the expression of substance P/calcitonin gene-related peptide/phosphorylated extracellular signal-regulated kinase 1/2 ([@b26-etm-0-0-4773]). In the current randomized controlled trial, no significant differences in the frequency of anorexia, nausea or vomiting were observed between the CTH+R and CTH groups. Notably, it was determined that patients with NSCLC in the CTH+R group exhibited more severe CTH-induced neutropenia than patients in the CTH group, however both groups had similar PFS and OS. Previous studies have demonstrated that CTH-induced neutropenia is an independent factor of better survival in patients with lung cancer ([@b8-etm-0-0-4773]--[@b11-etm-0-0-4773]), therefore it has been suggested that rikkunshito may exert potential effects on disease control when used in combination with the CDDP+GEM CTH regimen. Abnormal expression of transport protein, enhancement of intracellular detoxification, an increase in DNA repair capacity and the blocking of apoptosis are the primary mechanisms underlying cancer resistance to CDDP ([@b27-etm-0-0-4773]). Furthermore, ginseng radix, one of the primary ingredients of rikkunshito, has been found to exert antitumor, antioxidant, and immunomodulation activities through its pro-apoptotic and anti-cell cycle effects ([@b28-etm-0-0-4773]--[@b30-etm-0-0-4773]). The netropenic effect may only occur when rikkunshito is used in combination with anti-cancer drugs, since such an effect is not universally recognized under its general usage.

Microarray gene expression comparison between pre- and post-treatment data for the CTH+R and CTH groups identified a number of signaling pathways and molecules that were significantly altered following the addition of rikkunshito. Enhanced PTGS1 expression is responsible for persistent neutrophil presence as it impairs its apoptosis ([@b31-etm-0-0-4773]). It has been demonstrated that JAM3 regulates the polarized transendothelial migration of neutrophils ([@b32-etm-0-0-4773]), whereas the exogenous expression of AMICA1 (JAML) in leukocytes resulted in enhanced cell adhesion to endothelial cells ([@b33-etm-0-0-4773]). In the present study, *PTGS1*, *JAM3* and *AMICA1* were all down-regulated following rikkunshito treatment, indicating the underlying mechanisms by which more severe neutropenia was able to develop in the CTH+R group compared with the CTH group. In accordance with the results of the current study, it has been demonstrated that rikkunshito is able to inhibit the infiltration of neutrophils and macrophages by inhibiting the 5-HT3 receptor and ghrelin release in an animal model ([@b34-etm-0-0-4773]). Moreover, rikkunshito can ameliorate bleomycin-induced acute lung injury by inhibiting neutrophil alveolar infiltration, pulmonary vascular permeability, the release of pro-inflammatory cytokines, nuclear factor-κB pathway activation and the apoptosis of alveolar epithelial cells in a ghrelin-independent manner ([@b35-etm-0-0-4773]). The three serine proteases *ELANE*, *PRTN3* and *CTSG* are major components of the neutrophil primary granules ([@b36-etm-0-0-4773]--[@b38-etm-0-0-4773]). Previous studies have demonstrated that neutrophil *ELANE* provides a negative feedback to granulopoiesis by direct antagonism of granulocyte colony-stimulating factor, whereas *PRTN3*-mediated caspase-3 activation and the *CTSG*-dependent pathway contribute to the spontaneous death of neutrophils ([@b36-etm-0-0-4773]--[@b38-etm-0-0-4773]). Furthermore, *CD24* ligation induces neutrophil death by depolarizing the mitochondrial membrane in a manner dependent on caspase-3 and caspase-9 and reactive oxygen species ([@b39-etm-0-0-4773]). In the present study, the three neutrophil granules and *CD24* genes were all up-regulated following rikkunshito treatment, indicating that it may enhance neutrophil apoptosis. Four human α-defensins from the granules of neutrophils (DEF A1-A4) can attract other immune cells, inducing the release of pro-inflammatory cytokines ([@b40-etm-0-0-4773]). BPI, stored in the primary azurophilic granula of neutrophil granulocytes, is able to efficiently kill Gram-negative bacteria ([@b41-etm-0-0-4773]). In the present study *DEF A1*, *A2*, *A3*, and *BPI* were all up-regulated following rikkunshito treatment, indicating a positive effect of rikkunshito on the individual cell-killing function of neutrophils but a negative effect on the recruitment and survival of neutrophils.

The principal inhibitory receptors expressed on NK cells are KIR (*KIR2DL1-3*, *KIR3DL1*), while activating receptors include FcγRIIIA, activating forms of KIR (KIR2DS, KIR3DS), KIR2B4 and NKG2D ([@b42-etm-0-0-4773]). The mounting of effective anti-tumor immune responses by cytotoxic NK cells via mediation of cancer stem cell lysis is important to facilitate tumor clearance ([@b43-etm-0-0-4773]). In the present study, a number of inhibitory receptors (*KIR2DL1-3*, *KLR*) and activating receptors (*KIR2DS5*, *NKG7*) were all up-regulated following rikkunshito treatment, indicating that rikkunshito may exert its potential anti-neoplasm effect by modulating the function of NK cells. CD19 and MS4A3 both serve important roles in B cell receptor (BCR) activation and signaling ([@b44-etm-0-0-4773],[@b45-etm-0-0-4773]), while the extracellular antigen recognizing domain is complexed with CD79A and CD79B that form the cytoplasmic tail of the BCR ([@b46-etm-0-0-4773]). TNFRSF13B affects T-cell-independent antibody responses ([@b47-etm-0-0-4773]) and PRL may promote the increased proliferation of lymphocytes ([@b48-etm-0-0-4773]). In the present study, *CD19*, *MS4A3*, *CD79A*, *CD79B*, *TNFRSF13B*, *TNFRSF17* and *PRL* were all up-regulated following rikkunshito treatment, indicating that it may enhance the activation and proliferation of B cells.

F13A1 and MPL serve important roles in coagulation and thrombosis, respectively ([@b49-etm-0-0-4773],[@b50-etm-0-0-4773]), whereas IFITs are involved in drug resistance and metastasis in breast cancer ([@b51-etm-0-0-4773]). In response to vascular damage, engagement of the platelet receptors GP Ib-IX-V, GPVI and/or FcγRIIa leads to platelet adhesion and activation ([@b52-etm-0-0-4773]). A complex coagulopathy characterized by activation of clotting mechanisms develops in parallel with malignancy ([@b53-etm-0-0-4773]). In the present study, *F13A1*, *MPL*, GP Ib, *GPIX, GP IIb*, *IFIT1* and *IFIT2* were all down-regulated following rikkunshito treatment, indicating that rikkunshito may exert an anti-neoplasm effect, resulting in the down-regulation of these coagulation/thrombosis pathways.

It has been demonstrated that compromised immune surveillance and inflammatory microenvironments affect aspects of malignancy including proliferation, survival, angiogenesis and tumor metastasis. Neutrophils are recruited to tumor sites through transendothelial migration. This creates an inflammatory environment, which increases the risk of cancer development. By contrast, T cells and NK cells are able to recognize and destroy cancer cells ([@b54-etm-0-0-4773]). Antibodies that inhibit the checkpoint molecules of T cells, including cytotoxic T-lymphocyte-associated antigen 4 and programmed death legend 1, improve the survival and response to treatment in patients with NSCLC ([@b55-etm-0-0-4773]). Based on the rikkunshito-related genetic signatures, rikkunshito may have multiple pharmaceutical action sites to exert its anti-cancer effects by enhancing neutrophil apoptosis, inhibiting neutrophil migration, promoting NK cell activation, inducing B cell proliferation and ameliorating thrombosis/coagulation pathways. However, further studies are required to determine the exact pharmacological sites of rikkunshito with regard to its antitumor effects.

The limitations and biases of the current study should be addressed. First, only 17 patients with NSCLC were included in the current study and follow-up was completed over short-course study period. The sample size seems to be too small to accurately identify whether there were any significant differences in the major outcomes between the CTH and CTH+R groups. However, despite the small sample size, a greater neutropenic effect following the addition of rikkunshito treatment was observed in the current study. The lack of anti-emetic effect following rikkunshito treatment in the current randomized controlled trial may be due to strong anti-emetic agents, including the 5-HT3 receptor antagonists, metoclopramide and dexamethasone administered, to all 17 participants. Secondly, hemoglobin levels were lower and age was slightly greater in the CTH+R group at baseline. However, the maximum changes following treatment revealed that rikkunshito primarily affected white blood cell and neutrophil count, rather than hemoglobin levels. Moreover, Cox regression model analysis was performed to adjust the effect of the confounding factors on clinical outcomes. Finally, the changes in gene expression identified by the microarray analysis were not validated by quantitative real-time reverse transcript polymerase chain reaction due to the inadequate number of RNA samples. Despite these limitations, to the best of our knowledge, the present study is the first to assess the potential molecular mechanisms and genes associated with the clinical effects of rikkunshito on a genome-wide scale.

In conclusion, the current study identified the potential effect of rikkunshito treatment on reducing blood total leukocyte and absolute neutrophil counts in patients with advanced NSCLC receiving first line CTH with CDDP and GEM. Rikkunshito did not exert a prominent anti-emetic effect or affect other outcomes, including response rates and survival. Microarray gene expression analyses identified a number of signaling pathways and gene sets that may be involved in the underlying mechanisms by which rikkunshito functions to enhance the cell-killing ability of neutrophils, activate NK cells and B cell proliferation and inhibit coagulation/thrombosis. Gene Ontology analyses suggest that *PTGS1*, *MPL*, *AMICA1* and *JAM3* may be involved in the development of more severe CT-induced neutropenia by inhibiting neutrophil apoptosis whereas *ELANE*, *PRTN3*, *CTSG* and *CD24* may act by enhancing the transendothelial migration and adhesion of neutrophils following the addition of rikkunshito.
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![One-year survival analysis for the patients with lung cancer treated with CTH alone (CDDP+GEM) or CTH + rikkunshito. (A) Kaplan-Meier estimates of 1-year progression free survival (P=0.390, Log-Rank test). (B) Kaplan-Meier estimates of 1-year overall survival (P=0.058, Log-Rank test). (C) Kaplan-Meier estimates demonstrated that patients ≤60 years old had a better 1-year survival rate than those \>60 years old (P=0.015, Log-Rank test). CTH, cisplatin (CDDP)-based chemotherapy; CDDP, cisplatin; GEM, gemcitabine.](etm-14-03-2040-g00){#f1-etm-0-0-4773}

![Three-year survival analysis for the patients with lung cancer patients treated with CTH alone (CDDP+GEM) or CTH + rikkunshito. (A) Kaplan-Meier estimates of 3-year progression free survival (P=0.591, Log-Rank test). (B) Kaplan-Meier estimates of 3-year overall survival (P=0.261, Log-Rank test). CTH, cisplatin (CDDP)-based chemotherapy; CDDP, cisplatin; GEM, gemcitabine.](etm-14-03-2040-g01){#f2-etm-0-0-4773}

![Rikkunshito-regulated signaling pathways. Microarray-identified signaling pathways enriched following the addition of rikkunshito in the chemotherapy regimen for the advanced non-small cell lung cancer patients. The majority of these genes targeted insulin, cyclin-dependent kinase 1, Grb-2-related adaptor protein 2 and interleukin-2.](etm-14-03-2040-g02){#f3-etm-0-0-4773}

###### 

Comparison of the baseline characteristics of CTH and the CTH+R group.

  Characteristic                                CTH group, n=8   CTH+R group, n=9   P-value
  --------------------------------------------- ---------------- ------------------ ---------
  Age, years                                    56.7±15          67.5±8.7           0.135
    Male, n (%)                                 6 (75)               7 (77.8)       0.893
  TNM tumor stage, n (%)                                                            0.086
    IIIb                                        6 (75)               3 (33.3)       
    IV                                          2 (25)               6 (66.7)       
  Histology, n (%)                                                                  0.893
    Adenocarcinoma                              6 (75)               7 (77.8)       
    Squamous cell carcinoma                     2 (25)               2 (22.2)       
  ECOG performance status                                                           0.363
    0                                           0 (0)                2 (22.2)       
    1                                               7 (87.5)         6 (66.7)       
    2                                               1 (12.5)         1 (11.1)       
  Co-morbidity, n (%)                                                               
    Diabetes mellitus                               1 (12.5)         2 (22.2)       0.600
    Hypertension                                4 (50)               4 (44.4)       0.819
    Chronic bronchitis                              5 (62.5)         3 (33.3)       0.229
    Chronic hepatitis                               1 (12.5)         1 (11.1)       0.929
    Chronic kidney disease                      0 (0)                1 (11.1)       0.331
    Congestive heart failure                        1 (12.5)     0 (0)              0.274
  Smoking history, n (%)                                                            0.959
    Never                                           3 (37.5)         4 (44.4)       
    Former                                      4 (50)               4 (44.4)       
    Current                                         1 (12.5)         1 (11.1)       
  Mean dosage of chemotherapy agent (mg/m^2^)                                       
    Cisplatin                                   67.4±6.2         69.2±6.9           0.590
    Gemcitabine                                 973.1±65.1       968.7±82.4         0.782

All data are presented as the mean ± standard deviation unless otherwise specified. CTH, combination chemotherapy group; CTH+R group, combination chemotherapy plus rikkunshito group.

###### 

Comparison of the treatment responses and toxicity between the CTH group and the CTH+R group.

  Variable                                                                                    CTH group, n=8                  CTH+R group, n=9                  P-value
  ------------------------------------------------------------------------------------------- ---------------- -------------- ------------------ -------------- -----------------------------------------------------
  Treatment response, n (%)                                                                                                                                     0.415
    Partial response                                                                          2 (25)                          4 (44.4)                          
    Stable disease                                                                              3 (37.5)                      4 (44.4)                          
    Progressive disease                                                                         3 (37.5)                      1 (11.1)                          
    Change of tumor size (maximum diameter), cm                                               −0.075±2.12                     0.532±1.29                        0.501
  Events of toxicity                                                                          All              CDC grade ≥3   All                CDC grade ≥3   
    Anorexia                                                                                  22               2              24                 1              
    Nausea                                                                                    12               1              20                 1              
    Vomiting                                                                                    8              1              20                 2              
    Fatigue                                                                                   29               3              44                 4              
    Dyspnea                                                                                     6              1                3                1              
    Anemia                                                                                      6              0              14                 2              
    Neutropenia                                                                               10               4                6                2              
    Thrombocytopenia                                                                            1              0                4                0              
  Blood data                                                                                                                                                    
    White cell count at baseline, cells/µl                                                    5,885±841                       8,111±2,659                       0.052
    Absolute neutrophil count at baseline                                                     3,628±916                       5,326±2,960                       0.168
    Absolute monocyte count at baseline                                                       50.5±43.3                       47.6±19.6                         0.859
    Absolute lymphocyte count at baseline                                                     220±127.8                       192.8±92.3                        0.628
    Hemoglobin at baseline, g/dl                                                              14.2±1.2                        12.1±1.6                          0.014^[a](#tfn3-etm-0-0-4773){ref-type="table-fn"}^
    Platelets at baseline, 1,000/µl                                                           223.4±40.3                      311.4±107.1                       0.600
    ^[b](#tfn4-etm-0-0-4773){ref-type="table-fn"}^Max. Change of white cell count, cells/µl   58.6±1,760                      −2,125.6±1,750                    0.034^[a](#tfn3-etm-0-0-4773){ref-type="table-fn"}^
    ^[b](#tfn4-etm-0-0-4773){ref-type="table-fn"}^Max. Change of absolute neutrophil count    −593±1,938                      −3,206±2,242                      0.030^[a](#tfn3-etm-0-0-4773){ref-type="table-fn"}^
    ^[b](#tfn4-etm-0-0-4773){ref-type="table-fn"}^Max. Change of absolute lymphocyte count    −104±553                        −184±717                          0.491
    ^[b](#tfn4-etm-0-0-4773){ref-type="table-fn"}^Max. Change of absolute monocyte count      96±120                          −71±251                           0.138
    ^[b](#tfn4-etm-0-0-4773){ref-type="table-fn"}^Max. Change of hemoglobin, g/dl             −1.24±0.84                      −1.04±1.62                        0.916
    ^[b](#tfn4-etm-0-0-4773){ref-type="table-fn"}^Max. Change of platelets, 1,000/µl          −18±23                          −586±932                          0.368

All data are presented as the mean ± standard deviation unless otherwise specified.

P\<0.05.

Value prior to treatment minus mean value of the lowest one following each course of chemotherapy treatment. CTC, National Cancer Institute Common Terminology Criteria; CTH, combination chemotherapy group; CTH+R group, combination chemotherapy plus rikkunshito group; Max., maximum.

###### 

Selected microarray gene sets significantly altered before and after chemotherapy in the CTH+R group and regulated in the opposite direction before and after chemotherapy in the CTH group by Gene Ontology analysis.

                                                                  Fold change                                
  --------------------------------------------------------------- ------------- ---------- ----------------- ---------------------------------------------------------------------------------
  Up-regulated DEGs                                                                                          
  Defense response to other organism and cell killing                                                        
    GNLY                                                          1.9396        −2.5559    ENSG00000115523   Granulysin
    LTF                                                           1.8497        −1.0959    ENSG00000012223   Lactotransferrin
    CAMP                                                          1.9233        1.0559     ENSG00000164047   Cathelicidin antimicrobial peptide
    DEFA3                                                         3.5452        1.1143     ENSG00000239839   Defensin, α 3, neutrophil-specific
    DEFA4                                                         3.1757        −1.1284    ENSG00000164821   Defensin, α 4, cortico statin
    PRF1                                                          1.6845        −1.7414    ENSG00000180644   Perforin 1 (pore forming protein)
    DDIT4                                                         2.0889        −1.0391    ENSG00000168209   DNA-damage-inducible transcript 4
    RNASE3                                                        2.2979        −1.0209    ENSG00000169397   Ribonuclease, RNase A family, 3
    CTSG                                                          3.1563        1.2024     ENSG00000100448   Cathepsin G
    MPO                                                           2.0649        1.1206     ENSG00000005381   Myeloperoxidase
    AZU1                                                          2.1764        −1.0712    ENSG00000172232   Azurocidin 1
    PGLYRP1                                                       1.6233        −1.0181    ENSG00000008438   Peptidoglycan recognition protein 1
    BPI                                                           2.1614        −1.0686    ENSG00000101425   Bactericidal/permeability-increasing protein Serine-type endopeptidase activity
    MMP8                                                          1.5489        1.0208     ENSG00000118113   Matrix metallopeptidase 8 (neutrophil collagenase)
    GZMB                                                          1.5678        −2.2774    ENSG00000100453   Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)
    PRTN3                                                         1.6904        −1.0385    ENSG00000196415   Proteinase 3
    ELANE                                                         2.8886        1.2484     ENSG00000197561   Elastase, neutrophil expressed
    LTF                                                           1.84967       −1.09597   ENSG00000012223   Lactotransferrin
    CTSG                                                          3.15631       1.2024     ENSG00000100448   Cathepsin G
    AZU1                                                          2.17641       −1.07115   ENSG00000172232   Azurocidin 1
  Down-regulated DEGs Blood coagulation and Leukocyte migration                                              
    MPL                                                           −1.7269       1.0134     ENSG00000117400   myeloproliferative leukemia virus oncogene
    PROS1                                                         −1.6932       −1.0417    ENSG00000184500   protein S (alpha)
    GP IX                                                         −2.1117       −1.5528    ENSG00000169704   glycoprotein IX (platelet)
    PF4V1                                                         −1.8459       −1.3522    ENSG00000109272   platelet factor 4 variant 1
    PPBP                                                          −1.5451       −1.4881    ENSG00000163736   pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
    F13A1                                                         −1.9439       1.0911     ENSG00000124491   coagulation factor XIII, A1 polypeptide
  Down-regulated DEGs Blood coagulation and Leukocyte migration                                              
    AMICA1                                                        −1.5582       1.2624     ENSG00000160593   Adhesion molecule, interacts with CXADR antigen 1
    JAM3                                                          −1.5204       −1.0827    ENSG00000166086   Junctional adhesion molecule 3
    ITGA2B                                                        −1.8320       −1.5962    ENSG00000005961   Integrin, α 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)
    GP1BB                                                         −1.9588       −1.4438    ENSG00000203618   Glycoprotein Ib (platelet), β polypeptide
  Integral component of plasma membrane                                                                      
    ABCA1                                                         −1.5772       1.2133     ENSG00000165029   ATP-binding cassette, sub-family A (ABC1), member 1
    TSPAN9                                                        −1.5341       −1.3441    ENSG00000011105   Tetraspanin 9
    CLEC1B                                                        −1.7081       −1.0492    ENSG00000165682   C-type lectin domain family 1, member B
    AQP9                                                          −1.5495       1.0015     ENSG00000103569   Aquaporin 9
    MMD                                                           −1.9804       −1.1803    ENSG00000108960   Monocyte to macrophage differentiation-associated
    CYBB                                                          −1.5066       1.2194     ENSG00000165168   Cytochrome b-245, beta polypeptide
    DAB2                                                          −1.7146       −1.0331    ENSG00000153071   Dab, mitogen-responsive phosphoprotein, homolog 2 (*Drosophila*)

CTH, combination chemotherapy group; CTH+R group, combination chemotherapy plus rikkunshito group; DEG, differentially expressed genes.

###### 

Selected microarray of DEGs significantly altered before and after chemotherapy in the CTH+R group and regulated in the opposite direction before to and after chemotherapy in the CTH group.

                                                                               Fold change                                                                                                                   
  ---------------------------------------------------------------------------- ------------- ---------- ----------------- ---------------------------------------------------------------------------------- --
  Up-regulated DEGs                                                                                                                                                                                          
  Surface molecules of B cells                                                                                                                                                                               
    CD19                                                                       1.9084        −1.7289    ENSG00000177455   CD19 molecule                                                                      
    MS4A1 (CD20)                                                               1.5698        −1.0989    ENSG00000156738   membrane-spanning 4-domains, subfamily A, member 1                                 
    CD24                                                                       1.5597        1.0210     ENSG00000272398   CD24 molecule                                                                      
    CD79A                                                                      2.0026        −1.5466    ENSG00000105369   CD79a molecule, immunoglobulin-associated α                                        
    CD79B                                                                      1.6759        −1.3398    ENSG00000007312   CD79b molecule, immunoglobulin-associated β                                        
    TNFRSF13B (CD267)                                                          1.5603        −1.3878    ENSG00000240505   tumor necrosis factor receptor superfamily, member 13B                             
    TNFRSF17 (CD268)                                                           1.5128        −1.0736    ENSG00000048462   tumor necrosis factor receptor superfamily, member 17                              
    PRL                                                                        1.52987       −1.16365   ENSG00000172179   Prolactin                                                                          
  Surface molecules of NK cells                                                                                                                                                                              
    KIR2DL1 (CD158A)                                                           1.5137        −2.1425    ENSG00000125498   Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1    
    KIR2DL2 (CD158B1)                                                          1.5478        −2.3593    ENSG00000277725   Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2    
    KIR2DL3 (CD158B2)                                                          1.5771        −1.8231    ENSG00000243772   Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3    
    KIR2DL4 (CD158D)                                                           1.6675        −1.7716    ENSG00000189013   Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4    
    KLRK1 (CD314)                                                              1.5105        −1.8145    ENSG00000213809   Killer cell lectin-like receptor subfamily K, member 1                             
    KLRD1 (CD94)                                                               1.5437        −1.7995    ENSG00000134539   Killer cell lectin-like receptor subfamily D, member 1                             
    KIR2DS5 (CD158G)                                                           1.5378        −2.2766    ENSG00000277650   Killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5   
  Down-regulated DEGs Positive regulation of neutrophil counts or activation                                                                                                                                 
    PTGS1                                                                      −1.8308       −1.0724    ENSG00000095303   Prostaglandin-endoperoxide synthase 1                                              
    PGRMC1                                                                     −1.7732       −1.0262    ENSG00000101856   Progesterone receptor membrane component 1                                         
    MPL                                                                        −1.72699      −1.30672   ENSG00000117400   Proto-oncogene, thrombopoietin receptor                                            
    AMICA1                                                                     −1.55819      −1.07045   ENSG00000160593   Adhesion molecule, interacts with CXADR antigen 1                                  
    CYBB                                                                       −1.50661      −1.10927                                                                                                        
    PPBP                                                                       −1.54508      −1.48807                                                                                                        
  Positive regulation by activated neutrophils                                                                                                                                                               
    IFIT1                                                                      −1.6140       1.2178     ENSG00000185745   Interferon-induced protein with tetratricopeptide repeats 1                        
    PF4V1                                                                      −1.3522       −1.8459    ENSG00000109272   Platelet factor 4 variant 1                                                        
    ITGA2B                                                                     −1.83201      −1.59619                                                                                                        

CTH, combination chemotherapy group; CTH+R group, combination chemotherapy plus rikkunshito group; DEG, differentially expressed genes; CD, cluster of differentiation.
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